Azelastine in Pollen-Induced Allergic Rhinitis
- 7 Downloads
The manifestation of rhinitic symptoms in 9 patients with grass pollen-induced rhinitis was studied during long term allergen exposure at physiological concentrations in the ‘Vienna Challenge Chamber’. Patients were pretreated with a single dose of azelastine (either 2.2mg orally or 0.28mg intranasally) or placebo. Nasal resistance was estimated by active anterior rhinomanometry every 15 minutes. Analysis of changes in nasal airways resistance demonstrated significant protection against allergen-induced nasal obstruction (p < 0.01) for azelastine administered by either route. The onset of action of treatment in relation to nasal obstruction was significantly more rapid for the nasal spray (135 minutes) than for the tablet (205 minutes) [p < 0.01] formulation. Similarly, the onset of effect derived from subjective assessment of symptom severity was markedly more rapid (60 minutes) after intranasal azelastine than after administration of the oral form (120 minutes). Tolerability of azelastine was good, with no side effects reported with either oral or intranasal therapy.
Unable to display preview. Download preview PDF.
- Horak F, Jäger S. The Vienna Challenge Chamber — a new method of allergy exposition tests. Wiener Klinische Wochenschrift 99: 509–510, 1987Google Scholar
- Lenhard G, Gerhardt G. Azelastine, a new drug in the treatment of allergic rhinitis. New England and Regional Allergy Proceedings 9: 366, 1988Google Scholar
- Rajakulasingam K, Polosa R, Holgate ST, Church MK, Howarth PH. Comparative nasal responses to bradykinin, kallidin and des-arg9 bradykinin in non-rhinitic and atopic rhinitic subjects. Clinical and Experimental Allergy 20 (Suppl. 1): 57, 1990Google Scholar
- Walsh S, Robinson C, Howarth PH. The nasal effects of prostaglandin D2 in non-rhinitic and atopic rhinitic subjects. Abstract. Clinical and Experimental Allergy 20: 115, 1990Google Scholar
- Weiler JM, Donnelly A, Campbell BH, Connell JT, Diamond L, et al. Multicentre, double-blind, multiple dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis. Journal of Allergy and Clinical Immunology 32: 801–811, 1988CrossRefGoogle Scholar
- Zechel HJ, Brock N, Lenke D, Achterrath-Tuckermann U. Pharmacological and toxicological properties of azelastine, a novel antiallergic agent. Arzneimittel-Forschung/Drug Research 31: 1184–1193, 1981Google Scholar